• image06

    The bottom Line is

    Excellence

  • image01

    The bottom Line is

    Depth

  • image02

    The bottom Line is

    Differentiation

  • image04

    The bottom Line is

    People

  • image03

    The bottom Line is

    Efficiency

  • image05

    The bottom Line is

    Happiness

Quarter I Results, FY 2014-15

Pharma Major, Lupin Ltd. reported its performance for the first quarter ending 30th June, 2014. These unaudited results were taken on record by the Board of Directors at a meeting in Mumbai today.

Lupin Receives the 2014 ASTD BEST Award for Learning & Development

Pharma Major Lupin Limited (Lupin) announced today that the company has received the prestigious American Society for Training and Development (ASTD) BEST Award for Learning & Development for the year 2014. The award recognizes organizations that leverage the learning function as a strategic business tool to get results and which create, support, and champion learning opportunities to drive performance and build a learning culture.

Lupin Launches Generic Cipro® for Oral Suspension in the US

Pharma Major Lupin Limited (Lupin) announced today that the company’s US subsidiary, Lupin Pharmaceuticals Inc. (LPI) has launched its Ciprofloxacin for Oral Suspension, 5 g/100 mL (250mg/5 mL) and 10 g/100 mL (500 mg/5 mL) in the US having received final approval from the FDA earlier.

Quarter IV & Annual Results, FY 2013-14 - Record Sales and Profits

Pharma Major, Lupin Ltd. reported its performance for the fourth quarter ending 31st March, 2014. These audited results were taken on record by the Board of Directors at a meeting in Mumbai today.

Lupin Inks Strategic Joint Venture Agreement with Yoshindo Inc

Pharma Major, Lupin  Limited  (Lupin) announced  today  that  it has entered  into a  strategic  joint  venture  agreement  with  Toyama  based  Japanese  pharmaceuticals  company,  Yoshindo  Inc.  (Yoshindo)  to  create  a  new  entity,  YL  Biologics  (YLB).  YLB  will  be  jointly managed  by  both  partners  and  will  be  responsible  for  conducting  clinical  development of certain Biosimilars including regulatory filings and obtaining marketing authorizations in Japan.

Lupin Appoints Theresa Stevens as Chief Corporate Development Officer

Pharma major Lupin today announced the appointment of Theresa Stevens as Chief Corporate Development Officer for its global operations. Theresa will assume full responsibility for global merger and acquisitions and specialty business strategy. Prior to joining Lupin, Theresa was with Aptalis pharma as the Chief Corporate Development Officer responsible for Mergers & Acquisitions (M&A), Strategy and Global Business Development.

Stock Price

FINANCIALS SNAPSHOT

Standing on the shoulders of sustained growth in the past, we have delivered the best growth numbers in the Industry for the last 6 years.

Read more
MEDIA CENTER

Lupin launches Generic Geodon® Capsules Receives final FDA Approval for its Generic Geodon® Capsules.

Read more
THE LUPIN STORY

The company was named after the Lupin flower because of the inherent qualities of the flower.

Read more

OUR GLOBAL WEBSITES

USA
Japan (Kyowa) JAPAN (I’rom)
South Africa
Australia
Philippines
Germany
NETHERLANDS
MEXICO